The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers

Thyroid

Volumn 23, Issue 2, 2013, Pages 209-218

  Li, Xinying ^a,b   Abdel Mageed, Asim B ^a   Mondal, Debasis ^a   Kandil, Emad ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 HYDROXYNONENAL; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ACETYLSALICYLIC ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CURCUMIN; EPOXOMICIN; I KAPPA B; I KAPPA B BETA; I KAPPA B KINASE; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; JANUS KINASE; LACTACYSTIN; LACTACYSTIN BETA LACTONE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITRICOXIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN; PROTEIN P50; SANGUINARINE; SN 50; TOLL LIKE RECEPTOR; TRIPTOLIDE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSOLIC ACID;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA BINDING; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; GENE PRODUCT; HASHIMOTO DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOLECULAR INTERACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CARCINOMA; UBIQUITINATION;

HUMANS; NF-KAPPA B; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 84873615156     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0237     Document Type: Article

References (104)

1. Howlader N NA, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD. Available online at http://seer.cancer.gov/csr/1975-2009-pops09 (based on November 2011 SEER data submission, posted to the SEER web site April 2012).
2. Patel KN, Shaha AR 2006 Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13:119-128.
3. Schlumberger M, Sherman SI 2012 Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 166:5-11.
4. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F, Santoro M, Fusco A 1997 Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 15:1987-1994.
5. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P, Consiglio E, Formisano S, Leonardi A 2004 Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 279:54610-54619.
6. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S 2006 BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147:5699-5707.
7. Sen R, Baltimore D 1986 Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47:921-928.
8. Thornburg NJ, Pathmanathan R, Raab-Traub N 2003 Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 63:8293-8301.
9. Gupta SC, Sundaram C, Reuter S, Aggarwal BB 2010 Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 1799:775-787.
10. Oeckinghaus A, Hayden MS, Ghosh S 2011 Crosstalk in NF-kappaB signaling pathways. Nat Immunol 12:695-708.
11. Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G 2004 Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci 117:5197-5208.
12. Zhang Y, Chen F 2004 Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase ( JNK). Cancer Res 64:1902-1905.
13. Chung JY, Park YC, Ye H, Wu H 2002 All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 115:679-688.
14. Wajant H, Henkler F, Scheurich P 2001 The TNF-receptorassociated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal 13:389-400.
15. Vasudevan KM, Gurumurthy S, Rangnekar VM 2004 Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 24:1007-1021.
16. Park S, Zhao D, Hatanpaa KJ, Mickey BE, Saha D, Boothman DA, Story MD, Wong ET, Burma S, Georgescu MM, Rangnekar VM, Chauncey SS, Habib AA 2009 RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaBmediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN. Cancer Res 69: 4107-4111.
17. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS 2008 Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 22:1490-1500.
18. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y 1999 TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 4:1041-1049.
19. Sizemore N, Leung S, Stark GR 1999 Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 19:4798-4805.
20. Reddy SA, Huang JH, Liao WS 1997 Phosphatidylinositol 3-kinase in interleukin 1 signaling. Physical interaction with the interleukin 1 receptor and requirement in NFkappaB and AP-1 activation. J Biol Chem 272:29167-29173.
21. Ravi R, Mookerjee B, van Hensbergen Y, Bedi GC, Giordano A, El-Deiry WS, Fuchs EJ, Bedi A 1998 p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res 58:4531-4536.
22. Huang WC, Ju TK, Hung MC, Chen CC 2007 Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NFkappaB. Mol Cell 26:75-87.
23. Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A 2007 The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol) 19:154-161.
24. Luo JL, Kamata H, Karin M 2005 IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115:2625-2632.
25. Malara N, Foca D, Casadonte F, Sesto MF, Macrina L, Santoro L, Scaramuzzino M, Terracciano R, Savino R 2008 Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells. Cell Cycle 7:3235-3245.
26. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341.
27. Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Mitsiades N 2006 Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 91:3662-3666.
28. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457.
29. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Jr., Knauf JA, Zhang L, Taira K, Fagin JA 2006 BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147:1014-1019.
30. Tuyt LM, Dokter WH, Birkenkamp K, Koopmans SB, Lummen C, Kruijer W, Vellenga E 1999 Extracellularregulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes. J Immunol 162:4893-4902.
31. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762.
32. Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, Di Blasi F, Pitrone M, Zerilli M, Amato MC, Spinelli G, Carina V, Modica G, Latteri MA, Galluzzo A, Giordano C 2011 BRAFV600E mutation, TIMP-1 upregulation, and NF-kappaB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer 18:669-685.
33. Neely RJ, Brose MS, Gray CM, McCorkell KA, Leibowitz JM, Ma C, Rothstein JL, May MJ 2011 The RET/PTC3 oncogene activates classical NF-kappaB by stabilizing NIK. Oncogene 30:87-96.
34. Nagy R, Ganapathi S, Comeras I, Peterson C, Orloff M, Porter K, Eng C, Ringel MD, Kloos RT 2011 Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid 21:505-510.
35. Gujral TS, van Veelen W, Richardson DS, Myers SM, Meens JA, Acton DS, Dunach M, Elliott BE, Hoppener JW, Mulligan LM 2008 A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Res 68:1338-1346.
36. Kroll TG 2004 Molecular events in follicular thyroid tumors. Cancer Treat Res 122:85-105.
37. Yang D, Zhang H, Hu X, Xin S, Duan Z 2012 Abnormality of p16/p38 MAPK/p53/Wip1 pathway in papillary thyroid cancer. Gland Surg 1:33-38.
38. Edwards CQ, Griffen LM, Kushner JP 1991 Coincidental hemochromatosis and viral hepatitis. Am J Med Sci 301: 50-54.
39. Karger S, Weidinger C, Krause K, Sheu SY, Aigner T, Gimm O, Schmid KW, Dralle H, Fuhrer D 2009 FOXO3a: a novel player in thyroid carcinogenesis? Endocr Relat Cancer 16:189-199.
40. Tan A, Etit D, Bayol U, Altinel D, Tan S 2011 Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol 15:108-116.
41. Puppin C, Passon N, Frasca F, Vigneri R, Tomay F, Tomaciello S, Damante G 2011 In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription. Cell Oncol (Dordr) 34:131-140.
42. Malaguarnera R, Vella V, Vigneri R, Frasca F 2007 p53 family proteins in thyroid cancer. Endocr Relat Cancer 14:43-60.
43. Bauerle KT, Schweppe RE, Haugen BR 2010 Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer 9:117.
44. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA 2000 PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289:1357-1360.
45. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, Cheng SY 2006 PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 25:2736-2747.
46. Balkwill F, Mantovani A 2001 Inflammation and cancer back to virchow? Lancet 357: 539-545.
47. Ben-Neriah Y, Karin M 2011 Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12:715-723.
48. Arif S, Blanes A, Diaz-Cano SJ 2002 Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 41:357-362.
49. Asioli S, Erickson LA, Lloyd RV 2009 Solid cell nests in Hashimoto's thyroiditis sharing features with papillary thyroid microcarcinoma. Endocr Pathol 20:197-203.
50. Ahn D, Heo SJ, Park JH, Kim JH, Sohn JH, Park JY, Park SK, Park J 2011 Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer. Acta Oncol 50:1228-1234.
51. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM 2007 Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 204:764-773; discussion 773-765.
52. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP 1999 Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 84:458-463.
53. Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G, Sizemore N 2005 The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and betacatenin. Oncogene 24:1021-1031.
54. Pufnock JS, Rothstein JL 2009 Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J Immunol 182:5498-5506.
55. Russell JP, Engiles JB, Rothstein JL 2004 Proinflammatory mediators and genetic background in oncogene mediated tumor progression. J Immunol 172:4059-4067.
56. Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM 2011 Monitoring a nuclear factorkappaB signature of drug resistance in multiple myeloma. Mol Cell Proteomics 10:M110 005520.
57. Liu J, Qu X, Xu L, Zhang Y, Qu J, Hou K, Liu Y 2010 Phosphoinositide 3-kinase/Akt and nuclear factor kappaB pathways are involved in tumor necrosis factor-related apoptosis-inducing ligand resistance in human gastric cancer cells. Mol Med Report 3:491-496.
58. Kim DS, Park SS, Nam BH, Kim IH, Kim SY 2006 Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66:10936-10943.
59. Hayden MS, Ghosh S 2008 Shared principles in NF-kappaB signaling. Cell 132:344-362.
60. Bonizzi G, Karin M 2004 The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288.
61. Garrison JB, Samuel T, Reed JC 2009 TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB. Oncogene 28:1584-1593.
62. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV 1996 TRAF6 is a signal transducer for interleukin-1. Nature 383:443-446.
63. Shikama Y, Yamada M, Miyashita T 2003 Caspase-8 and caspase-10 activate NF-kappaB through RIP, NIK and IKKalpha kinases. Eur J Immunol 33:1998-2006.
64. Kopp E, Ghosh S 1994 Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956-959.
65. Rossi A, Elia G, Santoro MG 1997 Inhibition of nuclear factor kappa B by prostaglandin A1: an effect associated with heat shock transcription factor activation. Proc Natl Acad Sci USA 94:746-750.
66. Spiecker M, Liao JK 1999 Assessing induction of I kappa B by nitric oxide. Methods Enzymol 300:374-388.
67. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S 2000 Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289:1550-1554.
68. Weerasinghe P, Hallock S, Liepins A 2001 Bax, Bcl-2, and NF-kappaB expression in sanguinarine induced bimodal cell death. Exp Mol Pathol 71:89-98.
69. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB 2003 Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res 63:4375-4383.
70. Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky SA, Gautam SC 2004 Curcumin sensitizes prostate cancer cells to tumor necrosis factorrelated apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther 3:803-812.
71. Dauletbaev N, Lam J, Eklove D, Iskandar M, Lands LC 2010 Ibuprofen modulates NF-kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells. Respiration 79:234-242.
72. Gasparian AV, Guryanova OA, Chebotaev DV, Shishkin AA, Yemelyanov AY, Budunova IV 2009 Targeting transcription factor NFkappaB: comparative analysis of proteasome and IKK inhibitors. Cell Cycle 8:1559-1566.
73. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T 1994 The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773-785.
74. Roccaro AM, Vacca A, Ribatti D 2006 Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 1:397-403.
75. Williams AJ, Dave JR, Tortella FC 2006 Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NFkappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem Int 49:106-112.
76. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C 2001 Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7:1419-1428.
77. Daroczi B, Kari G, Ren Q, Dicker AP, Rodeck U 2009 Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos. Mol Cancer Ther 8:2625-2634.
78. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA, Conley BA 2005 Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent headand-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63:1400-1412.
79. Cusack JC, Jr., Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS, Jr. 2001 Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61:3535-3540.
80. Bielinska A, Baier L, Hailat N, Strahler JR, Nabel GJ, Hanash S 1991 Expression of a novel nuclear protein in activated and in tat-I expressing T cells. J Immunol 146:1031-1036.
81. Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S, Manda T, Tomoi M, Kida I, Higaki J, Kaneda Y, Shimomura K, Ogihara T 1999 Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 6:91-97.
82. Zhang S, Won YK, Ong CN, Shen HM 2005 Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents 5:239-249.
83. Garcia-Pineres AJ, Lindenmeyer MT, Merfort I 2004 Role of cysteine residues of p65/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci 75:841-856.
84. Torgerson TR, Colosia AD, Donahue JP, Lin YZ, Hawiger J 1998 Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NFkappa B p50. J Immunol 161:6084-6092.
85. Umezawa K 2006 Inhibition of tumor growth by NFkappaB inhibitors. Cancer Sci 97:990-995.
86. Shoji S, Furuishi K, Ogata A, Yamataka K, Tachibana K, Mukai R, Uda A, Harano K, Matsushita S, Misumi S 1998 An allosteric drug, o,o¢-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kappa B. Biochem Biophys Res Commun 249:745-753.
87. Tang KT, Lee CH 2010 BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 73:113-128.
88. O'Neill CJ, Bullock M, Chou A, Sidhu SB, Delbridge LW, Robinson BG, Gill AJ, Learoyd DL, Clifton-Bligh R, Sywak MS 2010 BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 148:1139-1145; discussion 1145-1136.
89. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M 2006 BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12:1623-1629.
90. Ahmed KM, Dong S, Fan M, Li JJ 2006 Nuclear factorkappaB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells. Mol Cancer Res 4:945-955.
91. Kim BY, Kim KA, Kwon O, Kim SO, Kim MS, Kim BS, Oh WK, Kim GD, Jung M, Ahn JS 2005 NF-kappaB inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation. Carcinogenesis 26:1395-1403.
92. Yeh PY, Yeh KH, Chuang SE, Song YC, Cheng AL 2004 Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation. J Biol Chem 279:26143-26148.
93. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S 2003 The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl + cells sensitive and resistant to STI571. Blood 102:3765-3774.
94. Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, Cheng AL 2002 Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer druginduced NF kappa B activation. Biochem Pharmacol 63: 1423-1430.
95. Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY 2007 Oncogenic BRAF regulates beta-Trcp expression and NFkappaB activity in human melanoma cells. Oncogene 26:1954-1958.
96. Liu D, Xing M 2008 Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid 18:853-864.
97. Yang F, Jove V, Chang S, Hedvat M, Liu L, Buettner R, Tian Y, Scuto A, Wen W, Yip ML, Van Meter T, Yen Y, Jove R 2012 Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-kB signaling, and synergizes with an ERK inhibitor. Cancer Biol Ther 13:349-357.
98. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R 2007 Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13:5291-5294.
99. Richardson PG, Hideshima T, Anderson KC 2003 Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10:361-369.
100. Wunderlich A, Arndt T, Fischer M, Roth S, Ramaswamy A, Greene BH, Brendel C, Hinterseher U, Bartsch DK, Hoffmann S 2012 Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. J Surg Oncol 105:357-364.
101. Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, Xie J, He S, Qiu P, Yan G 2009 A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol 75:812-819.
102. Stenner F, Liewen H, Zweifel M, Weber A, Tchinda J, Bode B, Samaras P, Bauer S, Knuth A, Renner C 2008 Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci 99:1847-1852.
103. Zhu W, He S, Li Y, Qiu P, Shu M, Ou Y, Zhou Y, Leng T, Xie J, Zheng X, Xu D, Su X, Yan G 2010 Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells. Vascul Pharmacol 52:46-54.
104. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N 2006 Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 91:4013-4021.